Perception of Cure Among Patients With Metastatic Cancer

The Perception of Cure Among Patients With Metastatic Cancer

This study collects information about perception of cure among patients with cancer that has spread to other places in the body (metastatic). This study aims to determine patients' perception (knowledge) before starting immunotherapy and if differences exist in understanding of treatment to stimulate or restore the ability of the body's immune (defense) system to fight infection and disease (immunotherapy) based on social and economic factors or on race/ethnicity.

Study Overview

• Status: Withdrawn
• Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Metastatic Malignant Solid Neoplasm
• Intervention / Treatment: Other: Survey Administration; Other: Electronic Medical Record

Detailed Description

PRIMARY OBJECTIVE:

I. To assess the proportion of patients with metastatic cancer who anticipate cure before starting immunotherapy.

SECONDARY OBJECTIVES:

I. To determine if expectations of cure are associated with quality of life and distress.

II. To determine if patients' perceptions differ by gender, age, and ethnicity.

OUTLINE:

Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.

• Study Type: Observational

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • City of Hope Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with metastatic cancer

Description

Eligibility Criteria:

1. Patients must be aged 18 and over
2. Patients sufficiently fluent in English
3. Patients must have a cytologically or pathologically verified diagnosis of cancer
4. Patients must have measurable metastatic disease
5. Patients must be initiating immunotherapy
6. Patients must be undergoing evaluation and treatment at City of Hope Cancer Center

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Observational (survey, medical records review); Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.	Other: Survey Administration; Complete surveys; Other: Electronic Medical Record; Medical records are reviewed; Other Names: Computer Based Patient Record; EMR; EMR (electronic medical record)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients	Will assess the percentage of patients who anticipate cure before starting immunotherapy, scoring a '1' on the Perception of cure tool, and anticipate >75% chance for a cure.	Up to 2 years
Patient Reported Outcomes Measurement Information System (PROMIS)	Descriptive analyses (e.g. frequency statistics) will be used to characterize the sample and to look at the association between Patient Reported Outcomes Measurement Information System (PROMIS) tool score with perception of cure score.	Up to 2 years
Functional Assessment of Cancer Therapy-General (FACT-G)	Descriptive analyses (e.g. frequency statistics) will be used to characterize the sample and to look at the association between Functional Assessment of Cancer Therapy-General (FACT-G) overall score with perception of cure score.	Up to 2 years
Perceptions of cure	Chi-square analyses will be used to examine perceptions of cure by sociodemographic characteristics: gender (male and female), age (< 60 and > 60), and ethnicity (white non-Hispanic, Hispanic, and other).	Up to 2 years

Collaborators and Investigators

• Sponsor: City of Hope Medical Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Sumanta K Pal, City of Hope Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): October 30, 2021
• Primary Completion (Actual): January 5, 2022
• Study Completion (Actual): January 5, 2022

Study Registration Dates

• First Submitted: March 25, 2021
• First Submitted That Met QC Criteria: March 25, 2021
• First Posted (Actual): March 29, 2021

Study Record Updates

• Last Update Posted (Actual): May 23, 2025
• Last Update Submitted That Met QC Criteria: May 22, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplastic Processes; Neoplasms; Neoplasm Metastasis
• Other Study ID Numbers: 19322 (Other Identifier: City of Hope Medical Center); P30CA033572 (U.S. NIH Grant/Contract); NCI-2021-01818 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No